戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 eing gathered regarding processes related to poor adherence.
2 rosis and identifies factors associated with poor adherence.
3 accepted, its effectiveness is undermined by poor adherence.
4 defined as good adherence and 80% or less as poor adherence.
5 65.0%, and 7.7%, respectively) for detecting poor adherence.
6  for inadequate clinical response because of poor adherence.
7 tion for a subset; predictors of good versus poor adherence.
8  to 1.55) were independently associated with poor adherence.
9 nd 9-month immunoglobulin G (IgG), which has poor adherence.
10 ercise have shown promise but are limited by poor adherence.
11 tients, due to interoperator variability and poor adherence.
12 orticosteroid dosing could indicate previous poor adherence.
13  pregnancy is often not well tolerated, with poor adherence.
14 as used to determine factors associated with poor adherence.
15 s, taking >= 1 medication, who self-reported poor adherence.
16 medically treated glaucoma and self-reported poor adherence.
17 k factors were statistically associated with poor adherence.
18 eness of sleep apnea treatment is limited by poor adherence.
19 failure rates in typical use, due largely to poor adherence.
20  for treatment of opioid use disorder due to poor adherence.
21                     There were five cases of poor adherence.
22 ppointing results were attributed largely to poor adherence.
23  Twenty-seven percent of the sample reported poor adherence.
24 s (CIs) identifying barriers associated with poor adherence.
25 d toward patients with such risk factors for poor adherence.
26 s for whom poor asthma control is related to poor adherence.
27 ation schedule were barriers associated with poor adherence.
28 re shown to be an independent risk factor of poor adherence.
29 ucoma medication and factors associated with poor adherence.
30 efined, yet multiple studies have identified poor adherence.
31 oporosis treatments is determining causes of poor adherence.
32 ing medications, even at very high levels of poor adherence.
33 models, respectively); (2) persistently very poor adherence (14.9% and 23.4% of persons in the 1- and
34 ents whose imatinib doses were increased had poor adherence (86.4%).
35 iodemographic characteristics helped explain poor adherence (African Americans: low maternal educatio
36               Of these patients, 8 (13%) had poor adherence and 36 (55%) had moderate adherence.
37  participants, 20.0% (n = 147) self-reported poor adherence and 6.1% (n = 45) had EHR documentation o
38 gical interventions that are associated with poor adherence and adverse effects.
39  poor lung function distinguished those with poor adherence and frequent errors in technique.
40 , failure of prophylaxis was associated with poor adherence and low plasma drug levels.
41 e in actual clinical practice are limited by poor adherence and low prescription rates.
42 ion, it is necessary to analyze the cause of poor adherence and make a concrete action plan.
43 t is lengthy, expensive, and associated with poor adherence and notable morbidity and mortality.
44 mes by not including those at higher risk of poor adherence and reinfection--individuals for whom rea
45 r which current treatments may be limited by poor adherence and residual vision deficits.
46 e and costly for patients, consequently with poor adherence and restricted access to therapy for many
47 ch that first identifies patients at risk of poor adherence and then seeks to establish the support t
48 d concerns of adverse outcomes subsequent to poor adherence and/or self-cessation/loss-to-follow-up.
49 gnificant difference between good adherence, poor adherence, and dropout regarding level of understan
50  but these regimens are limited by toxicity, poor adherence, and low cure rates.
51 uate prescription of antiretroviral therapy, poor adherence, and repeated interfaces with congregate
52 a by health-care provider, and management of poor adherence; and patients in the control group receiv
53                     Antiviral resistance and poor adherence are the most important factors in treatme
54                  Most of these patients have poor adherence because of multiple factors, and hence in
55                                Nevertheless, poor adherence but not optimal or improving adherence ca
56 land but is associated with side-effects and poor adherence by patients, and TMP-SMX alone is recomme
57 d survey on factors behind dropout cases and poor adherence cases.
58  87 (10%) of the 854 treatment months showed poor adherence compared with 290 (37%) of the 795 months
59 g >=1 glaucoma medication, who self-reported poor adherence) completed a baseline survey that assesse
60                                              Poor adherence contributes to uncontrolled asthma.
61  DH not controlled by gluten-free diet (with poor adherence), dapsone, and conventional immune-suppre
62 to mercaptopurine (57.1% vs 40.9%); however, poor adherence did not completely explain the associatio
63 oroquine, but they have limitations, such as poor adherence due to frequent oral administration and g
64                     Interventions to prevent poor adherence during sheltering may be more useful for
65                                     However, poor adherence during sheltering occurred in 1034 adults
66                         Those with predicted poor adherence exhibited markedly lower CPAP use than th
67 atients with RR/MDR-TB who exhibited initial poor adherence followed by subsequent improvement achiev
68 TDM represents a useful tool to discriminate poor adherence from real cases of resistant hypertension
69  regression slopes of viral RNA load for the poor-adherence group were significantly higher than thos
70 herence group), or neither of the above (the poor-adherence group).
71           In the comparison between good and poor adherence groups, except four dropout patients, the
72 ents at risk and to target interventions for poor adherence has increased.
73 ective, low persistence in PrEP programs and poor adherence have limited its ability to reduce HIV in
74 hird had drug concentrations consistent with poor adherence, highlighting the need for novel approach
75 ght be a key noninvasive resource to address poor adherence in children and adolescents in a clinical
76  future directions for assessing the risk of poor adherence in clinical settings.
77 s associated with a lower risk of death than poor adherence in patients with CHF, irrespective of ass
78                      Factors associated with poor adherence include psychiatric, psychological and em
79                                      Because poor adherence increases the risk of glaucoma progressio
80 positive airway pressure (CPAP) therapy, but poor adherence is common and is associated with worse pa
81                                              Poor adherence is common in difficult-to-control asthma.
82                                As in adults, poor adherence is the major obstacle to successful conti
83               Identifying factors predicting poor adherence is therefore essential.
84 engthy and onerous, and hence complicated by poor adherence leading to drug resistance and disease re
85                                              Poor adherence leads to antiretroviral (ARV) resistance,
86                                              Poor adherence leads to reduced effectiveness, increased
87 sive treatment regimens that compensated for poor adherence led to better improvements in glycemic co
88 o accessibility to subsequent cART regimens, poor adherence limiting scope to switch regimens, and th
89 etween those with physiologically predicted "poor" adherence (lowest quartile of predicted adherence)
90 th CML treated with imatinib for some years, poor adherence may be the predominant reason for inabili
91 o receive samples will be considered to have poor adherence), misidentification of newly treated pati
92 nately, initial CPAP intolerance may lead to poor adherence or abandonment of therapy.
93 icult as there are no existing biomarkers of poor adherence or inadequate treatment earlier than 2 mo
94 or 100-fold concentration differences due to poor adherence or less frequent prescribed dosing, vagin
95  the concept of pseudo-resistance, linked to poor adherence or other factors, and provide an algorith
96                                              Poor adherence or persistence to treatment can be a barr
97 elect for a resistant subpopulation, whereas poor adherence or second-line therapy resulted in the re
98 ause patients do not take their medications (poor adherence) or because providers do not increase med
99 r deselecting patients with high prior cost, poor adherence, or response to treatments.
100 e and 6.1% (n = 45) had EHR documentation of poor adherence (P < .0001).
101 rved in 60% of cases and was associated with poor adherence (p<0.001) and subsequent development of d
102 ases in efforts to overcome low service use, poor adherence rates, and stigma.
103 chieve HIV RNA suppression by 6 months, with poor adherence, rather than HIV drug resistance, driving
104                                              Poor adherence represents a major threat for TB control
105 th persistent low CD4 cell counts because of poor adherence, resistance to antiretroviral drugs, or b
106  (RR, 6.75; 95% CI, 1.11-70.9; P = .036) and poor adherence (RR, 7.50; 95% CI, 1.23-78.7; P = .026).
107 e identify several variables associated with poor adherence such as glaucoma progression, LTF, younge
108 ns in addressing modifiable risk factors for poor adherence (such as depression, stress, and lower ed
109 occur with oral quinine because of the known poor adherence to 7-d regimens.
110                                              Poor adherence to a gluten-free diet, HLA-DQ2 homozygosi
111 cholesterolemia) that could be attributed to poor adherence to a healthy lifestyle, we calculated the
112 ng young women that might be attributable to poor adherence to a healthy lifestyle.
113 9% to 89%) of CHD cases were attributable to poor adherence to a healthy lifestyle.
114                 We considered the factors of poor adherence to and dropout from sublingual immunother
115                                              Poor adherence to anticoagulant therapy is also an issue
116 od, hygiene, and shelter needs), followed by poor adherence to antiretroviral therapy, not having a c
117                                              Poor adherence to antiretroviral treatment regimens has
118                Inadequate dose titration and poor adherence to basal insulin can lead to suboptimal g
119                                              Poor adherence to both corticosteroids predicted signifi
120 that IPs reported inadequate drug provision, poor adherence to clinical national guidelines, and that
121 symptoms can be poorly controlled because of poor adherence to controller therapy, and this might be
122 y to refractive amblyopia as they often have poor adherence to daily glasses wearing.
123 tions may be acceptable to veterans who have poor adherence to existing evidence-based treatments for
124                                     There is poor adherence to guidelines in regard to use of anti-MR
125                         These findings imply poor adherence to guidelines in the diagnosis and manage
126                               In conclusion, poor adherence to hemodialysis treatments may be a subst
127                                              Poor adherence to HIV protease inhibitors may compromise
128                      Factor A was defined as poor adherence to ICS or ICS/LABA inhaler of 75% or less
129                              We suggest that poor adherence to insulin treatment is the major factor
130 Poor disease control was not associated with poor adherence to irrigation use.
131                                              Poor adherence to maintenance treatment is an important
132          Reluctance to seek intervention and poor adherence to management strategies make behavior-or
133                                              Poor adherence to medication is common in some chronic i
134 l or other drug abuse problems combined with poor adherence to medication may signal a higher risk of
135                                              Poor adherence to medication regimens is common, potenti
136                                              Poor adherence to medication regimens may be contributin
137 e term hypertension or its cause, leading to poor adherence to medications and limiting other effecti
138 ased emergency department use for asthma and poor adherence to medications.
139  of more than 1000 copies per mL (signifying poor adherence to oral drugs, and often associated with
140                                              Poor adherence to oral HIV pre-exposure prophylaxis (PrE
141    Fifty-eight percent of patients exhibited poor adherence to prescribed antihypertensive medication
142 he limited efficacy of existing medications, poor adherence to prescribed regimens, and a heightened
143                                              Poor adherence to prescribed therapies is common in pati
144 zability of these findings is complicated by poor adherence to reporting guidelines and high risk of
145         Available data suggest that there is poor adherence to SSTI treatment guidelines.
146                                 We find that poor adherence to such drugs causes treatment failure vi
147 ute to ineffective cancer pain management is poor adherence to the analgesic regimen.
148 e over the course of the trial, resulting in poor adherence to the assigned study treatment and a red
149  Subtherapeutic drug levels can be caused by poor adherence to the drug regimen, interactions with ot
150 trials have reported varying efficacy due to poor adherence to the drug.
151 se aspects of care; however, physicians show poor adherence to the guidelines despite the evidence th
152 Plasma tenofovir concentrations demonstrated poor adherence to the study product among study subjects
153 eral prescription medications sometimes have poor adherence to their treatment regimens.
154  (<8.0 g/dL; AHR, 3.1; 95% CI, 2.3-4.0), and poor adherence to therapy (AHR, 2.9; 95% CI, 2.2-3.9).
155                      Given the prevalence of poor adherence to therapy and the biases of self-reporti
156                                              Poor adherence to therapy makes it unlikely that the sig
157              Presence of FNf did not reflect poor adherence to therapy.
158  therapy and this is often associated with a poor adherence to therapy.
159 nderutilization of therapy by providers, and poor adherence to treatment among patients.
160                                              Poor adherence to treatment diminishes its individual an
161                                              Poor adherence to treatment may be one of the mechanisms
162  provider reliance on clinical diagnosis and poor adherence to treatment policy, especially in first
163         Treatments for OUD may be limited by poor adherence to treatment recommendations and by high
164 dy fat, which leads to further morbidity and poor adherence to treatment.
165 tly due to absence of implementation of, and poor adherence to, medications.
166                                              Poor adherence was a major determinant of virological fa
167 he proportion of patients with self-reported poor adherence was compared between the EHR extraction a
168                                              Poor adherence was defined as adherence of less than 50%
169                      Factors associated with poor adherence were less than 12 yr of formal education
170                                   Those with poor adherence were modeled as having outcomes similar t
171 40, taking >=1 medication, who self-reported poor adherence were recruited from the University of Mic
172 nhanced hand hygiene protocols were met with poor adherence, whereas pharmacists consistently engaged
173 utcome variability, especially the impact of poor adherence, which is critical to manage PrEP in the
174 in patients with cystic fibrosis, indicating poor adherence, which is particularly common in adolesce
175 ble for isoniazid preventive therapy and the poor adherence with a complete regimen among those we in
176 een associated with poor quality of life and poor adherence with antiretroviral therapy.
177 ack of health insurance, and no access to or poor adherence with controller medications such as inhal
178 amivudine-dolutegravir (TLD) can result from poor adherence with or without resistance; however, geno
179 nt to at least 30% of surveyed patients with poor adherence, with most identifying multiple barriers
180                                              Poor adherence, younger age, and more comorbidities were

 
Page Top